D-Day Approaches For Bayer’s Asundexian Phase III Plans
Factor XIa Inhibitor Impressive So Far
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.
You may also be interested in...
Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.